Akari Therapeutics Plc (AKTX): Nasdaq/NYSE listing notice — Akari Therapeutics receives Nasdaq delisting notice for stockholders' equity deficit

Akari Therapeutics Plc

Stockholders' deficit of $229,000 at Dec 31, 2023 violates Nasdaq's $2.5M minimum equity requirement.
Company received delisting notice on April 5, 2024; must submit compliance plan by May 20, 2024.
If Nasdaq accepts plan, extension possible through Oct 2, 2024 to regain compliance.
Failure to regain compliance may result in delisting; company can request hearing to stay.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Akari Therapeutics Plc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

April 5, 2024, Akari Therapeutics, Plc (the “Company”) received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Capital Market (“Nasdaq”) notifying the Company that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”) is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity

View on SEC.gov

Browse all listing & compliance notices →

Akari Therapeutics Plc filing history →

Source: SEC EDGAR

accession 0000950170-24-043519

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.